{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:10:49Z","timestamp":1793650249157,"version":"4.5.1"},"reference-count":18,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,10,13]],"date-time":"2014-10-13T00:00:00Z","timestamp":1413158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabet. Med."],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>To examine the relationship between visual acuity in each eye and Quality of Life (QoL) outcomes in people with diabetic macular oedema.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Cross sectional retrospective analysis of data collected at baseline in 289 people entered into a randomized clinical trial with diabetic macular oedema which investigated the safety and efficacy of a vascular endothelial growth factor inhibitor, pegaptanib sodium. At the baseline visit, visual acuity was measured through refraction and using retro\u2010illuminated modified Early Treatment Diabetic Retinopathy Study Log <jats:styled-content style=\"fixed-case\">MAR<\/jats:styled-content> charts, and patient health\u2010related QoL was determined using the European Quality of Life <jats:styled-content style=\"fixed-case\">EQ<\/jats:styled-content>\u20135D\u20133L and the Visual Functioning Questionnaire\u201325 (<jats:styled-content style=\"fixed-case\">NEI<\/jats:styled-content>\u2013<jats:styled-content style=\"fixed-case\">VFQ<\/jats:styled-content>25). A regression analysis with QoL score from each vision\u2010related domain as the dependent variable was fitted using linear and quadratic terms of the better and worse eye, age, gender, adjusted for number of concurrent conditions, ethnicity and level of diabetes control.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>For all vision\u2010related QoL domains from <jats:styled-content style=\"fixed-case\">NEI<\/jats:styled-content>\u2013<jats:styled-content style=\"fixed-case\">VFQ<\/jats:styled-content>25 and <jats:styled-content style=\"fixed-case\">EQ<\/jats:styled-content>\u20135D\u20133L except ocular pain, both visual acuity in the better\u2010seeing and the worse\u2010seeing eye gave a significant increase in correlation coefficient over that obtained from clinical and demographic data. The <jats:styled-content style=\"fixed-case\">NEI<\/jats:styled-content>\u2013<jats:styled-content style=\"fixed-case\">VFQ<\/jats:styled-content>25 correlation was most closely associated with a weighted visual acuity measure of 0.75 in the better and 0.25 in the worse eye or 0.60 in the better and 0.40 in the worse eye.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We recommend that a weighted visual acuity measure from both eyes is considered in future diabetic macular oedema trials.<\/jats:p><\/jats:sec>","DOI":"10.1111\/dme.12593","type":"journal-article","created":{"date-parts":[[2014,9,24]],"date-time":"2014-09-24T01:53:44Z","timestamp":1411523624000},"page":"97-101","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The use of weighted health\u2010related Quality of Life scores in people with diabetic macular oedema at baseline in a randomized clinical trial"],"prefix":"10.1111","volume":"32","author":[{"given":"P. H.","family":"Scanlon","sequence":"first","affiliation":[{"name":"Gloucestershire Diabetic Retinopathy Research Group Gloucestershire Hospitals NHS Foundation Trust Cheltenham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Loftus","sequence":"additional","affiliation":[{"name":"Pfizer Ltd Walton Oaks UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Starita","sequence":"additional","affiliation":[{"name":"Pfizer Ltd Walton Oaks UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. M.","family":"Stratton","sequence":"additional","affiliation":[{"name":"Gloucestershire Diabetic Retinopathy Research Group Gloucestershire Hospitals NHS Foundation Trust Cheltenham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,10,13]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"International Diabetes Federation.IDF Diabetes Atlas 2013. Available athttp:\/\/www.idf.org\/diabetesatlasLast accessed 16 April 2014."},{"key":"e_1_2_9_3_1","first-page":"844","article-title":"Global data on visual impairment in the year 2002","volume":"82","author":"Resnikoff S","year":"2004","journal-title":"Bull World Health Org"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2013.196"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-008-0960-y"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2007.122416"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.02.045"},{"key":"e_1_2_9_8_1","first-page":"45","article-title":"An interpretation of quality of life based on binocular visual acuity in German patients with age\u2010related macular degeneration","author":"Pleil AM","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_9_9_1","unstructured":"EuroQol Group.EQ\u20105D User Guide 2013. Available athttp:\/\/www.euroqol.org\/about-eq-5d\/publications\/user-guide.htmlLast accessed 16 April 2014."},{"key":"e_1_2_9_10_1","volume-title":"The Measurement and Valuation of Health: Final Report on the Modelling of Valuation Tariffs","author":"MVH_Group","year":"1995"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.119.7.1050"},{"key":"e_1_2_9_12_1","unstructured":"Clinical Trials.gov.A Multi\u2010Center Trial to Evaluate the Safety and Efficacy of Pegaptanib Sodium (Macugen) Injected into the Eye Every 6 Weeks for up to 2\u00a0Years for Macular Swelling Associated with Diabetes with an Open\u2010Label Macugen Year Extension. Available atclinicaltrials.gov\/ct2\/show\/results\/NCT00605280Last accessed 16 April 2014."},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.86.1.8"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2005.01736.x"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/0264619608097745"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-8992"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.08.002"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.3109\/09286586.2014.888456"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2415-13-74"}],"container-title":["Diabetic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdme.12593","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dme.12593","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dme.12593","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dme.12593","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T20:11:11Z","timestamp":1696363871000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dme.12593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,13]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1111\/dme.12593"],"URL":"https:\/\/doi.org\/10.1111\/dme.12593","archive":["Portico"],"relation":{},"ISSN":["0742-3071","1464-5491"],"issn-type":[{"value":"0742-3071","type":"print"},{"value":"1464-5491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,13]]},"assertion":[{"value":"2014-05-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-09-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-10-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}